Search
Showing results for "mental health aboriginal"
A The Kids Research Institute Australia study designed to gauge community awareness of respiratory syncytial virus (RSV) has found parents and parents-to-be are highly aware of the virus and are open to immunisation to tackle it.
How protective is the whooping cough vaccine? Vaccination and allergy Even though Australia has high vaccination rates against whooping cough, we
The Wesfarmers Centre is pleased to announce the successful applications for the 2018 Round 1 Wesfarmers Centre Seed Funding. The Wesfarmers Centre
COVID-19 27 June 2021 Update: It is business as usual for ORIGINS, though masks must be worn.
The ORIGINS Project’s Early Moves study is investigating whether a baby’s early movements can predict learning difficulties later in childhood.
The WA Kids Cancer Centre brings together clinicians and researchers working together to defeat childhood cancer.
Dr Jessica Buck and Associate Professor Raelene Endersby have been appointed to the prestigious Australian Brain Cancer Mission Expert Advisory Panel.
Infants with KMT2A-rearranged B-cell precursor acute lymphoblastic leukemia (ALL) have poor outcomes. There is an urgent need to identify novel agents to improve survival. Proteasome inhibition has emerged as a promising therapeutic strategy for several hematological malignancies. The aim of this study was to determine the preclinical efficacy of the selective proteasome inhibitor carfilzomib, for infants with KMT2A-rearranged ALL.
Unlike adults, malignant melanoma in children and adolescents is rare. In adult melanoma, significant progress in understanding tumor biology and new treatments, including targeted therapies and immunotherapy have markedly improved overall survival. In sharp contrast, there is a paucity of data on the biology and clinical behavior of pediatric melanoma. We report a national case series of all pediatric and adolescent malignant melanoma presenting to ANZCHOG Childhood Cancer Centers in Australia and New Zealand.
Infants with KMT2A-rearranged B-cell precursor acute lymphoblastic leukemia (ALL) have poor outcomes. There is an urgent need to identify novel agents to improve survival. Proteasome inhibition has emerged as a promising therapeutic strategy for several hematological malignancies. The aim of this study was to determine the preclinical efficacy of the selective proteasome inhibitor carfilzomib, for infants with KMT2A-rearranged ALL.